This ITK/RLK dual inhibitor was approved for the treatments of T-cell or NK cell malignancies as well as inflammatory and autoimmune diseases, such as psoriasis, psoriatic arthritis, rheumatoid arthritis, multiple sclerosis, and irritable bowel disease (Fuhriman et al., 2018; Zhong et al., 2015). Here, ITK is linked to rheumatoid arthritis.